Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Status:
Withdrawn
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This research study is a way of gaining new knowledge about a drug called olaparib in women
who have either: 1)never received a PARP inhibitor before to treat ovarian cancer (group 1)
or 2)participants who have received a PARP inhibitor before to treat ovarian cancer, with the
exception of olaparib (group 2). PARP inhibitors are drugs tht prevent cancer cells from
repairing their DNA. In this research study, we are looking to see how well the drug olaparib
works in women who have never received a PARP inhibitor for recurrent ovarian cancer as well
as those who have received a prior PARP inhibitor and whose cancer has re-grown after
receiving that PARP inhibitor.